Energesis Pharmaceuticals, Inc

Antagen Pharmaceuticals Inc., based in Canton, Massachusetts, is a pioneering biotechnological company committed to developing innovative solutions for pressing healthcare challenges, including infectious diseases, cancer, and autoimmune disorders. With a mission focused on revolutionizing healthcare through advanced research and technology platforms, Antagen is at the forefront of delivering cutting-edge biomedical services and products. Offering a comprehensive array of biotechnological services, Antagen specializes in therapeutic antibody development, recombinant protein production, and the development of COVID-19 detection kits. Their dedication to quality and innovation has garnered positive testimonials from clients who praise the company's expertise and reliability in the industry. Generated from the website

AVEO Oncology is a Boston-based biopharmaceutical company dedicated to improving the lives of cancer patients through innovative medical solutions. As a subsidiary of LG Chem, the company focuses on developing and delivering effective treatments that address the unique challenges faced by individuals battling cancer. Committed to scientific advancement, AVEO's portfolio includes several promising therapies, such as FOTIVDA, Ficlatuzumab, and AV-380. The company's mission is driven by a passion for enhancing the quality of life for those affected by cancer, underscoring their focus on patient-centered care. Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.